In: NEOPLASMA, vol. 52, no. 3
P. Rzepecki - J. Zolnierek - T. Sarosiek - P. Langiewicz - C. Szczylik
Detaily:
Rok, strany: 2005, 238 - 242
O článku:
We evaluated the efficacy of allogeneic non-myeloablative stem
cell transplantation (NST) in patients with metastatic
renal cell carcinoma (RCC). A total of 5 patients received blood
stem cells from HLA identical siblings. Conditioning
consisted of: cyclophosphamide 60 mg/kg/d, days -7 to -6 and
fludarabine 25 mg/m2/d for consecutive days [days -5, -4, -3,
-2, -1].
The median CD34+ cell dose was 3.34 million/kg. Immunosuppression
consisted of cyclosporine A and methotrexate.
Among all, four patients achieved full donor chimerism with a
median of 89 days. One patient rejected the graft and received
the second transplantation. Grade II-III acute GVHD occured in 3
patients. None of patients achieved complete or partial response
and there were only two mixed responses. All patients died due to
cancer progression. There were no transplant-related
deaths. Summarising, NST regimen allows allogeneic engraftment
with low treatment related mortality in this
high-risk population of patients. Acute and chronic GVHD are the
major morbidities. Progression is common after NST in
unselected patients with advanced RCC. However, regression of some
metastases suggests that the graft versus tumor effect
may occur after this type of treatment. At present such a
procedure should be considered as an experimental approach.
Ako citovať:
ISO 690:
Rzepecki, P., Zolnierek, J., Sarosiek, T., Langiewicz, P., Szczylik, C. 2005. Allogeneic non-myeloablative hematopoietic stem cell
transplantation for treatment of metastatic renal cell carcinoma -
single center experience. In NEOPLASMA, vol. 52, no.3, pp. 238-242. 0028-2685.
APA:
Rzepecki, P., Zolnierek, J., Sarosiek, T., Langiewicz, P., Szczylik, C. (2005). Allogeneic non-myeloablative hematopoietic stem cell
transplantation for treatment of metastatic renal cell carcinoma -
single center experience. NEOPLASMA, 52(3), 238-242. 0028-2685.